On February 7, 2025, the President of the United States issued an amended order as it pertains to the import rules for goods related to synthetic opioids from China, temporarily suspending the ‘de minimis’ provision until “notification by the Secretary of Commerce to the President that adequate systems are in place to fully and expediently process and collect tariff revenue…”

Previously, some of these goods were entered without paying duties if they were below a certain value, a provision known as “duty-free de minimis treatment.” This most recent order by the President revoked that privilege, but it is now restored. So the duty-free status will continue for now. However, once the Secretary of Commerce confirms that the necessary systems are in place to handle and collect the required duties, this duty-free status will end for these goods.

This change does not affect the authority of any government department or agency, nor does it alter the budgetary functions of the Office of Management and Budget. The order will be implemented in accordance with existing laws and subject to the availability of funding. It does not create any new legal rights that individuals can enforce against the government.

For more information, please visit Amendment to Duties Addressing the Synthetic Opioid Supply Chain in the People’s Republic of China – The White House.